However, three separate sets of primary outcomes were considered (insulin sensitivity, hepatic steatosis, subclinical chronic inflammation) and different mechanisms are discussed for the relevance of GI, GL or CHO from low- or higher-GI sources for these outcomes. The gene discussed is INS; the disease is Hepatic steatosis.